Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?

Diabetes and Metabolism

Volumn 45, Issue 6, 2019, Pages 501-504

  Valensi, P ^a,b   Picard, S ^c   Pathak, A ^d  

^a UNIVERSITÉ PARIS 13   (France)

^b Point Medical ^*  (France)

^c Point Medical   (France)

^d University Hospital of Toulouse   (France)

Author keywords

Cardiovascular disease; Chronic kidney disease; GLP 1 receptor agonist; Heart failure; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONSENSUS; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DIABETOLOGIST; ECHOCARDIOGRAPHY; EDITORIAL; ELECTROCARDIOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; EXERCISE TEST; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; SILENT MYOCARDIAL ISCHEMIA; COMPLICATION; COOPERATION; DIABETIC ANGIOPATHY; ECONOMICS; ENDOCRINOLOGIST; HEALTH CARE COST; INTERDISCIPLINARY COMMUNICATION; METHODOLOGY; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PREVENTIVE MEDICINE; PROCEDURES; RISK FACTOR;

CARDIOLOGISTS; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOCRINOLOGISTS; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; PREVENTIVE MEDICINE; RESEARCH DESIGN; RISK FACTORS;

EID: 85070996355     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2019.07.007     Document Type: Editorial

References (29)

1. Study Group ACCORD, Gerstein, H.C., Miller, M.E., Genuth, S., Ismail-Beigi, F., Buse, J.B., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
2. Mosenzon, O., Wiviott, S.D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E.L., et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol, 2019.
3. Davies, M.J., D'Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 (2018), 2669–2701.
4. Cosson, E., Nguyen, M.T., Chanu, B., Banu, I., Chiheb, S., Balta, C., et al. Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. Diabetes Care 34 (2011), 2101–2107.
5. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
6. Agarwal, S., Cox, A.J., Herrington, D.M., Jorgensen, N.W., Xu, J., Freedman, B.I., et al. Coronary calcium score predicts cardiovascular mortality in diabetes: diabetes heart study. Diabetes Care 36 (2013), 972–977.
7. Hacker, M., Becker, C., The incremental value of coronary artery calcium scores to myocardial single photon emission computer tomography in risk assessment. J Nucl Cardiol 18 (2011), 700–711.
8. Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., et al. SAVOR-TIMI 53 steering committee and investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
9. Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.M., et al. Risk Factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. Engl J Med 379 (2018), 633–644.
10. Castagno, D., Baird-Gunning, J., Jhund, P.S., Biondi-Zoccai, G., MacDonald, M.R., Petrie, M.C., et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162 (2011), 938–948.
11. Chow, E., Bernjak, A., Walkinshaw, E., Lubina-Solomon, A., Freeman, J., Macdonald, I.A., et al. Cardiac autonomic regulation and repolarization during acute experimental hypoglycemia in type 2 diabetes. Diabetes 66 (2017), 1322–1333.
12. Nunes, A.P., Iglay, K., Radican, L., Engel, S.S., Yang, J., Doherty, M.C., et al. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes Obes Metab 19 (2017), 1425–1435.
13. Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
14. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
15. Seferović, P.M., Petrie, M.C., Filippatos, G.S., Anker, S.D., Rosano, G., Bauersachs, J., et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European society of cardiology. Eur J Heart Fail 20 (2018), 853–872.
16. Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Bonaca, M.P., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
17. Verma, S., Mazer, C.D., Bhatt, D.L., Raj, S.R., Yan, A.T., Verma, A., et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care 42 (2019), e42–e44.
18. Lytvyn, Y., Bjornstad, P., Udell, J.A., Lovshin, J.A., Cherney, D.Z.I., Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136 (2017), 1643–1658.
19. Figtree, G.A., Rådholm, K., Barrett, T.D., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation 139 (2019), 2591–2593.
20. Januzzi, J., Ferreira, J.P., Böhm, M., Kaul, S., Wanner, C., Brueckmann, M., et al. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur J Heart Fail 21 (2019), 386–388.
21. Matthews, D.R., Li, Q., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia 62 (2019), 926–938.
22. Cosentino, F., Ceriello, A., Baeres, F.M.M., Fioretto, P., Garber, A., Stough, W.G., et al. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European society of cardiology cardiovascular roundtable. Eur Heart J, 2018.
23. Das, S.R., Everett, B.M., Birtcher, K.K., Brown, J.M., Cefalu, W.T., Januzzi, J.L. Jr., et al. 2018 ACC Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 72 (2018), 3200–3223.
24. Scheen, A.J., Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab 45 (2019), 110–121.
25. Vilsbøll, T., Bain, S.C., Leiter, L.A., Lingvay, I., Matthews, D., Simó, R., et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20 (2018), 889–897.
26. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jódar, E., Leiter, L.A., et al. SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
27. Hernandez, A.F., Green, J.B., Janmohamed, S., D'Agostino, R.B. Sr., Granger, C.B., Jones, N.P., et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
28. Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Diaz, R., Lakshmanan, M., Pais, P., et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394 (2019), 121–130.
29. Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 (2019), 2295–2306.